Senescence is a double-edged sword that can function in opposite directions. It is a potential mechanism for a cell to avoid malignant transformation. However, senescence can also promote cancer development by altering the cellular microenvironment through a senescence-associated secretory phenotype (SASP). At least, three types of cellular stress such as activation of oncogenes, loss of tumor suppressor genes, and chemo/radiotherapy can induce cell senescence. Oncogene-induced senescence can be intertwingly associated with the replicative senescence. Early-stage senescence may protect cell from transformation, while prolonged senescence often promotes cancer development. This review will focus on the characteristics of senescence, discuss the regulation of senescence during cancer development, and highlight the complexity of senescence that makes cancer treatment challenging.
INTRODUCTION
In 1965, Leonard Hayflick found that normal cells could not proliferate endlessly after doubling dozens of times. These cells gradually and eventually halted from dividing and became enlarged with many cytosolic granules. This phenomenon has been named "senescence". 1 The nondividing senescent cells remained viable, however, failed to respond to growth and death stimuli. The molecular characteristics of senescent cells usually include upregulation of cell-cycle inhibitors such as p21 and/or p16, 2 positive staining of senescence-associated β-galactosidase (SA-β-gal), 2 formation of senescence-associated heterochromatin foci (SAHF), 3 and the induction of senescence-associated DNA damage. 4 However, senescent cells usually do not obtain all the characteristics mentioned above. Senescent cells are a type of cells with irreversible cell-cycle arrest and apoptotic resistance. There are many types of senescence: replicative senescence, oncogene-induced senescence such as, and therapy-induced senescence. Oncogene-induced senescence can be viewed as a mechanism for an organism to prevent tumorigenesis. However, senescence occurring during cancer treatment may ambiguously impact tumor response, which unravels the complexity of senescence in vivo and also raises a question about the irreversibility of senescence. 5 This review clarifies the characteristics and regulation of senescence and discusses the complex role of senescence in cancer treatment.
THE BIOMARKERS OF SENESCENCE
Senescence-associated β-galactosidase Dimri et al. 6 discovered in 1995 that senescent fibroblast cells turned blue at pH 6.0 when 5-bromo-4-chloro-3-indolyl β-D-galactoside (X-gal) was added, while quiescent, terminally differentiated or immortal cells did not possess such a feature. Since then, β-gal assay has become a classical method to detect cellular senescence. β-gal can hydrolyze X-gal into galactose and 5-bromo-4-chloro-3-hydroxyindole, which dimerizes and oxidizes to a blue product, 5,5'-dibromo-4,4'-dichloro-indigo. 7 However, it was unknown why senescent cells express a high level of β-gal until Lee's report. 8 Lee et al. 8 demonstrated that SA-β-gal was expressed from the gene of lysosomal β-gal (GLB1). Fibroblasts with mutant GLB1 had low lysosomal β-gal activity at late passage even though
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Senescence-associated heterochromatin foci
When cells are stained with 4′,6-diamidino-2-phenylindole (DAPI), a fluorescent dye that binds strongly to A-T rich regions in DNA, senescent cells typically display one large nucleolus with punctate DNA foci known as SAHF. 9 These DAPI-staining punctate SAHF foci represent heterochromatin regions that are usually bound with heterochromatin proteins such as heterochromatin protein 1 (HP1) and hypoacetylated histones, 10 which may explain the altered gene expression when cells undergo senescence. Activated retinoblastoma protein (pRb) localizes to these foci and help remodel chromatin to form SAFH foci. 
Senescence-associated secretory phenotype
When performing a genome-wide small hairpin RNA screen to identify the genes required for blocking BRAF V600E -mediated cell proliferation, Wajapeyee et al. 12 detected a secreted protein named insulin growth factor binding protein 7. This protein can inhibit the proliferation of melanoma cells through the BRAF-MEK-ERK signaling pathway, revealing a secretory mechanism for senescent cells to avoid tumorigenesis. Besides growth factors, senescent cells can secrete cytokines and enzymes such as interleukin (IL)-1, IL-6, and IL-8 13 and metalloproteinase. 14 These secreted factors can exert diverse functions. On one hand, specific components of senescence-associated secretory phenotype (SASP) such as IGFBP 7, IL-6, and IL-8 may suppress tumor growth; 15 on the other hand, enzymatic components such as matrix metalloproteinase-3 (MMP-3) can promote tumor invasion and metastasis. 16 
THE CAUSES OF SENESCENCE Replicative senescence
Primary cells cannot divide permanently in culture. They usually undergo a permanent growth arrest and stop responding to external stimuli such as changes of the cultural condition. 1 Here is a question: what limits their proliferation. Telomere shortening may be one of the main causes. Telomere is a complex structure comprised repetitive DNA with associated proteins that caps the chromosomal ends and protects them from degradation or fusion during DNA-repair process. 17 Mutation of the ever shorter telomere 1 gene in yeast caused gradual loss of telomere sequence and resulted in a phenotype similar to senescence. 18 Later study by Harley et al. 19 showed that the number and length of telomeres were negatively correlated with the passage times of the cells. When human telomerase reverse transcriptase was supplemented to the telomerase-null fibroblasts, the telomeres of these cells became longer, and the cells division turned quicker with normal karyotype. These telomerase-supplemented fibroblasts could passage more than 20 times and displayed less β-gal staining than that of the telomerase-null fibroblasts. 20 All of the above evidence indicates that telomere shortening is one of the main causes for replicative senescence.
Replicative senescence possesses classic features of DNA double-strand breaks (DSBs), with activated ataxia telangiectasia mutated (ATM), and/or ATM and RAD3-related (ATR) and their respective mediators, checkpoint kinase 2 (CHK2) and CHK1. d' Adda di Fagagna et al. 21 found that damaged telomeres were associated with these DNA damage response proteins. When microinjected with combinations of plasmids expressing kinase-dead ATM (ATM-KD), ATR-KD, CHK1-KD, and CHK2-KD, senescent BJ cells could enter S phase to undergo proliferation, 21 indicating that damaged telomeres induced senescence by activating the DNA damage checkpoint pathways.
Oncogene-induced senescence
When transfected with oncogene such as SV40 large T or mutant hRAS, FS-2 cells (a diploid, human neonatal fibroblasts) preferentially entered cellular senescence but not transformation, 22 although the study by Serrano et al. 23 demonstrated that RAS could transform most of the mouse cells. In human primary cells, senescence can be induced by the upregulation of both p53 and p16 by oncogene, while inactivation of p53 or p16 can prevent cellular senescence. This demonstrates that the ectopic expression of oncogenes can induce senescence.
Similar to replicative senescence, oncogene-induced senescence also activates DNA damage response pathway. Overexpression of proto-oncogene serine/threonine-protein kinase mos (mos), cell division control protein 6 homolog (cdc6), or cyclin E activated the DNA damage checkpoint and induced senescence. 24 In precancerous lesions, robust activation of the DSB checkpoint is directly correlated with senescence. However, progression to carcinoma often abrogates this relationship, suggesting that, such as apoptosis, senescence may provide a barrier for tumor progression. 24 In addition to the activation of oncogenes, loss of tumor suppressor genes can also induce senescence. For example, acute inactivation of PTEN induced p53-mediated cellular senescence. 25 This PTEN-loss-induced cellular senescence (PICS) was further demonstrated to be distinct from oncogene-induced senescence. This special type of senescence occurred in the absence of cellular proliferation and DNA damage checkpoint response and can be targeted for cancer therapy. Specifically, inhibition of tumorigenesis was achieved by pharmacological inhibition of PTEN. 26 Interestingly, PTEN-null senescent cells secreted immunosuppressive cytokines through the Jak2/Stat3 pathway, pharmacological inhibition of which led to an antitumor immune response that enhances the efficacy of chemotherapy. 27 These results suggest that PTEN-deficient senescent tumor cells drive an immunosuppressive tumor microenvironment through SASP and that blocking the mediators and effectors of PICS may evoke antitumor immune surveillance.
Therapy-induced senescence
Cancer is a cluster of cells that acquire abnormal survival and growth behaviors. Chemotherapy or radiation therapy represents common strategies to kill these cancerous cells. However, these treatments inevitably confer toxicity and unwanted side effects. Fortunately, scientists have found that low-dose radiotherapy or chemotherapy can reduce side effect by promoting senescence in cancer cells.
Bleomycin is an anticancer drug that induces DNA strand breaks. Fibroblast cells treated with bleomycin exhibited DNA double-strand breakage but not apoptosis. 28 Cells then entered an extended cell-cycle arrest for at least 30 days, accompanied by the upregulation of p53/p21 and p16 in the early and late stage respectively. Thus, chemical agents that cause DNA strand breaks are sufficient to induce cellular senescence. Wang et al. 29 have shown that cisplatin could induce CNE1 cells, a nasopharyngeal carcinoma cell line, to undergo senescence-like cell-cycle arrest with typical morphological changes and elevated signals of β-gal. Moreover, a higher proportion of senescent cells were associated with lower doses of cisplatin. Later studies found that other chemical drugs such as hydroxyurea, 30 doxorubicin, 31 camptothecin 32 and 5-bromodeoxyuridine 33 can also induce cell senescence. These data indicate that DNA-damaging agent can induce senescence not only in primary cells but also in cancerous cells.
Like chemical drugs, radiation therapy can also elicit cell senescence. When exposed to > 4 Gy gamma ionizing radiation, normal fibroblasts underwent G1 arrest for longer than 3 weeks. Exposure to low-dose radiation caused G1 arrest in most cells although a few proceeded to DNA replication.
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SIGNALING PATHWAYS INVOLVED IN CELL SENESCENCE
Cellular events such as telomere shortening, 20 oncogene activation, 24 or chemo/radiotherapy 4, [28] [29] [30] [31] [32] [33] can induce cell senescence mainly through the activation of p53 or pRb. Mutation of p53 in embryonic fibroblasts prevents senescence and leads to uncontrolled cells proliferation. 34 Similarly, pRb mutation in a combination of inactivation of p107 and p130 can inhibit cellular senescence. 35, 36 It is believed that both p53 and pRb are important mediators of cellular senescence although they are involved in different cellular signaling pathways.
Cellular stress can activate p53 through diverse mechanisms. For example, telomere breakage or DNA damaging agents can induce DNA damage response, manifested by activation of ATM and ATR and subsequent activation of their respective mediators CHK2 and CHK1. Activated CHK2 or CHK1 can phosphorylate p53 and latter induces DNA damage repair or initiates cell senescence. 37 Activated p53 induces the transcription of p21, which blocks cell-cycle progression by inhibiting CDK2. 38 MDM2 is an E3 ligase that binds p53 to cause its degradation while blocking this pathway by p14 ARF represents another mechanism of p53 activation. 39 pRb is regulated not only by the p53-p21-CDK2 pathway 40 but also by p16-related pathways, especially in epithelial cells. p16, an inhibitor of the cyclinD-CDK4/6 complex, is not expressed in normal adult tissues 41 but highly expressed in senescent cells. 42 p16 is one of the most frequently mutant genes in human cancer, 43 deletion of which results in pRb inactivation and cell-cycle progression from G1 to S phase. Therefore, p16 and pRb form a tumor suppressor pathway and their mutations often occur in a mutually exclusive manner.
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p53 and pRb are also functionally interrelated. The p16
INK4a
and p14 ARF genes are located at the same locus with two shared exons. 45 Mutations of p16 INK4a usually inactivates these two genes, leading to simultaneous inhibition of both p53 and pRb. Another functional link between p53 and pRb has been demonstrated by a study showing that E2F-1, a transcription factor that is normally inhibited by pRb, can activate p53 by promoting the transcription of p14ARF. 46 Cellular senescence can also be induced by other mechanisms in a p53-and pRb-independent manner. Knockdown of the histone acetyltransferase p300 led to the global hypoacetylation of histones H3 and H4, formation of heterochromatin foci during S phase and production of lower-speed replication forks. Despite the lack of DNA damage checkpoint activation, cells were indeed arrested in G2/M phase and underwent senescence. Meanwhile, downregulation of p53 and p16 showed no influence on senescence induced by knockdown of p300, indicating that p300 regulates senescence in a p53-and p16-independent manner.
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THE REVERSE OF SENESCENCE
In senescent BJ cells, on inactivation of ATM, ATR, CHK1, and CHK2, 17% of the cells reentered S phase, 21 which questions the irreversibility of senescence. Dirac and Bernards 34 found that the suppression of p53 enabled a small proportion (about 0.5%-1%) of senescent embryonic fibroblasts to reenter the cell cycle. They used time-lapse photomicrographs to validate that these cells were originated from senescent cells. However, Kang et al. 48 suggested that senescence is reversible only in the early stage of senescence establishment, likely through the inactivation of p53 and pRb. These changes can no longer reverse senescence once the senescent state is formed and stabilized. They induced senescence by transducing E2 protein of bovine papillomavirus 1 and found that pRb inactivation by HPV E7 oncoprotein could reverse senescence in the early stage, but failed to do so 5 days after senescence establishment. Clearly, more research is needed to clarify the reversibility of senescence.
In addition to the reversibility of senescence, the secretory phenotype of senescence adds another layer of complexity in treating cancers. Condition culture media from senescent malignant pleural mesothelioma cells induced epithelial-to-mesenchymal transition (EMT) and resistance to chemotherapy due to high levels of secreted aldehyde dehydrogenase. 49 Laberge et al. 50 found that senescent fibroblasts could trigger EMT in surrounding epithelial cells. Collectively, these data suggest that senescent cells can change the tumor microenvironment and facilitate invasion, metastasis, and resistance to therapies.
CLINICAL APPLICATION OF SENESCENCE
Cytotoxic agents are often used in high doses to eliminate cancer cells, which unfortunately can give rise to severe side effects on normal cells. Alternatively, lower doses of the same agents may induce senescence in cancer cells 51 and avoid side effects on normal cells. Indeed, the induction of senescence is a popular strategy in cancer treatment, and ongoing clinical applications of such strategy include hydroxyurea, 30 doxorubicin, 31 camptothecin 32 and 5-bromodeoxyuridine. 33 Moreover, senescence can be induced by extracellular or intracellular stresses even in cancer cells with mutant p53 and/or pRb, suggesting that there are novel mechanisms independent of p53 and pRb. 43, 52, 53 Although senescence forms a barrier to tumorigenesis and senescent cells often remain dormant in vivo for months and even for years, once these dormant cancer cells reenter the cell cycle, tumorigenesis can resume, and cancer can relapse. 54 Meanwhile, senescent cells can secrete proteins such as MMP-3 to promote tumor invasion and metastasis.that senescence itself can be detrimental and serve as a target for therapy. Effective strategies to eradicate these harmful senescent cells are under research.
Baar et al. 56 found that FOXO4 is overexpressed in senescent cells. They, then synthesize a D-retro-inverso modified FOXO4 peptide to release p53, which interacts with FOXO4 in senescent cells and to induce senescent cells to undergo apoptosis in a p53-dependent manner. Oncolytic measles vaccine viruses are also used to eradicate senescent cells. 57 Treated with EB 1089, a vitamin D3 analog before radiotherapy, cells undergo apoptosis and skipped senescence. 58 These researches above confer a possibility to extinguish senescent cells occurring during chemo/radiotherapy.
CONCLUSION
Senescent cells are withdrawn from cell-cycle permanently and can be cleared by macrophages, neutrophils, or natural killer cells. 59, 60 However, they can maintain their senescent status for years and accumulate with age, 56 which confers a risk of reentering the cell cycle and promoting oncogenesis. On the other hand, senescence serves as a natural barrier to uncontrolled cell growth and malignant transformation. These miscellaneous roles of senescence pose a significant challenge to our efforts in targeting senescence-related pathways to treat cancers. More intensive research is needed to better understand the molecular mechanisms underlying the establishment, maintenance, and blockage of senescence, to clarify its reversibility, and to develop novel senescence-targeted strategies in anticancer treatment.
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